BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, May 4, 2024
See today's BioWorld
Home
» Coley Stock Plunges As Pfizer Abandons NSCLC Program
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Coley Stock Plunges As Pfizer Abandons NSCLC Program
June 21, 2007
By
Glen Harris
No Comments
Shares of Coley Pharmaceutical Group Inc. sank nearly 60 percent Wednesday on news that partner Pfizer Inc. has walked away from the investigation lung cancer drug PF-3512676, shelving two Phase III and two Phase II trials. (BioWorld Today)
BioWorld